Saturday 17 October 2026 Export NTLA’s income statement to Excel — free account

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.7 million, up 16.9% from fiscal 2024. In the quarter to June 2026, revenue fell 46.2%, EPS grew 18.4% and free cash flow grew 15.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.42 0.08 +0.71%

Follow NTLA

Alert me

Market cap: $1.6B
P/E: 0.0×
Fwd P/E: −4.3×
Dividend yield: —
F-score: 4/9
Altman Z: −1.93
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.40

Total sells 2.15

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	1	—	—	—	—	—	—	—	—	—
Sell	—	1	7	—	1	—	—	—	3	1	—	1

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1,590.00

Revenue 59.51

Net Income (399.97)

Free Cash Flow (348.60)

Net Debt (437.76)

Current Ratio 6.65

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (4.25)

P/S ratio 25.62

P/B ratio 2.09

Past 5Y EPS Growth —

This Y EPS Growth 16.05%

Next Y EPS Growth 17.90%

Next Y revenue growth (23.33%)

Next 5Y EPS Growth 24.19%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 38.56%

10-year low 10-year high

P/B against its own 10 years 20.66%

10-year low 10-year high

EV/Sales against its own 10 years 43.68%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	912	602	450	438
Receivables	36	9	9	7
Inventory	—	—	—	—
Other	—	—	—	—
	998	640	528	528

	2023	2024	2025	Q'26
Payables	7	15	20	12
ST’ Debt	—	—	—	—
Other	—	—	—	—
	115	111	104	79

Compound Annual Growth %

	10y	5y	3y
Sales	27.32%	3.13%	9.09%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	4.96%	(18.40%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	15	8	—	—	—
’25	17	14	14	23	68
’24	29	7	9	13	58
’23	13	14	12	(2)	36
’22	11	14	13	14	52
’21	6	7	7	13	33
’20	13	16	22	7	58

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(117)	(83)	—	—	—
’25	(149)	(100)	(77)	(69)	(395)
’24	(121)	(58)	(85)	(85)	(349)
’23	(109)	(90)	(101)	(93)	(394)
’22	(80)	(85)	(79)	(90)	(333)
’21	(52)	(53)	(65)	(55)	(225)
’20	(39)	57	(29)	(40)	(50)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(117)	(85)	—	—	—
’25	(150)	(100)	(77)	(69)	(396)
’24	(123)	(59)	(86)	(86)	(355)
’23	(113)	(95)	(106)	(95)	(408)
’22	(81)	(89)	(83)	(94)	(347)
’21	(55)	(56)	(70)	(58)	(238)
’20	(39)	56	(29)	(41)	(53)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.81)	(0.80)	—	—	—
’25	(1.10)	(0.98)	(0.92)	(0.83)	(3.81)
’24	(1.12)	(1.52)	(1.34)	(1.27)	(5.25)
’23	(1.17)	(1.40)	(1.38)	(1.46)	(5.42)
’22	(1.96)	(1.33)	(1.49)	(1.40)	(6.16)
’21	(0.69)	(1.01)	(0.97)	(1.09)	(3.78)
’20	(0.63)	(0.61)	(0.47)	(0.69)	(2.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	11.87	10.83	11.03	10.26	9.18	43.86	32.72	22.67	11.34	5.90	Analyst estimates 2026–2028 Powerpack
	High	30.40	33.34	35.99	19.00	70.00	202.73	119.65	47.48	34.87	28.25
People
People	Employees	104	195	211	270	312	485	598	526	403	377
	Revenue/emp, $m	0.16	0.13	0.14	0.16	0.19	0.07	0.09	0.07	0.14	0.18
Income, $m
Income, $m	Revenue	16	26	30	43	58	33	52	36	58	68
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(32)	(68)	(85)	(100)	(134)	(268)	(474)	(481)	(519)	(413)
	EBT margin, %	(191.97)	(258.62)	(280.42)	(230.92)	(231.46)	(810.49)	(909.78)	(1,326.51)	(896.77)	(609.85)
	Net income	(32)	(68)	(85)	(100)	(134)	(268)	(474)	(481)	(519)	(413)
	Depreciation	1	3	4	6	6	7	8	9	10	16
Per share, $
Per share, $	Revenue	0.74	0.73	0.71	0.91	1.04	0.47	0.68	0.41	0.59	0.62
	Earnings	(1.42)	(1.88)	(1.98)	(2.11)	(2.40)	(3.78)	(6.16)	(5.42)	(5.25)	(3.81)
	Cash flow	1.62	(1.81)	(1.42)	(2.19)	(0.89)	(3.17)	(4.33)	(4.44)	(3.53)	(3.64)
	Capex	(0.28)	(0.28)	(0.14)	(0.14)	(0.06)	(0.18)	(0.17)	(0.16)	(0.06)	(0.01)
	Free cash flow	1.35	(2.09)	(1.57)	(2.33)	(0.96)	(3.35)	(4.50)	(4.60)	(3.59)	(3.65)
	Book value	9.44	8.35	6.45	5.71	9.41	14.67	16.05	11.83	8.82	6.20
	Shares, m	22	36	43	47	56	71	77	89	99	108
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	18.18	29.65	19.32	16.08	52.52	253.61	54.00	76.86	19.91	14.40
	P/B	1.43	2.58	2.12	2.57	5.78	8.06	2.28	2.65	1.32	1.45
	EV/Sales	1.61	16.61	9.00	9.59	42.22	230.96	31.12	51.71	9.52	7.75
	EV/FCF	0.88	(5.76)	(4.06)	(3.76)	(45.77)	(32.10)	(4.68)	(4.60)	(1.55)	(1.32)
Cash, $m
Cash, $m	Operating cash flow	36	(65)	(61)	(103)	(50)	(225)	(333)	(394)	(349)	(395)
	Capex	(6)	(10)	(6)	(7)	(4)	(13)	(13)	(14)	(6)	(1)
	Free cash flow	30	(75)	(67)	(110)	(53)	(238)	(347)	(408)	(355)	(396)
Balance, $m
Balance, $m	Working capital	251	323	284	254	552	643	1,090	883	529	424
	Total debt	—	—	—	19	40	74	131	—	—	—
	Net debt	(273)	(341)	(314)	(280)	(597)	(749)	(1,193)	(912)	(602)	(450)
	Shareholders’ equity	210	301	278	270	527	1,040	1,236	1,050	872	671
Returns, %
Returns, %	ROA	(16.60)	(20.01)	(23.59)	(29.21)	(26.56)	(27.19)	(33.69)	(34.11)	(41.66)	(40.60)
	ROIC	0.00	0.00	0.00	0.00	0.00	(57.42)	(666.53)	(233.47)	(123.47)	(124.43)
	ROE	(33.54)	(26.46)	(29.50)	(36.34)	(33.69)	(34.18)	(41.67)	(42.10)	(54.00)	(53.48)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ZBIO Zenas BioPharma, Inc.	$1.7B	— (loss-making)	— (loss-making)	—	n/m	−37.12% (below 0%: shrinking)	100.00%	(10,765.90%)	Compare
OCUL Ocular Therapeutix, Inc.	$1.6B	— (loss-making)	— (loss-making)	+0.12% (above 0%: growing)	n/m	−25.35% (below 0%: shrinking)	85.08%	(609.34%)	Compare
NTLA Intellia Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−46.23% (below 0%: shrinking)	n/m	+15.05% (above 0%: growing)	100.00%	(1,472.25%)
STOK Stoke Therapeutics, Inc.	$1.6B	— (loss-making)	— (loss-making)	−32.51% (below 0%: shrinking)	n/m	−128.97% (below 0%: shrinking)	100.00%	(701.65%)	Compare
GPCR Structure Therapeutics Inc. Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−119.15% (below 0%: shrinking)	0.00%	0.00%	Compare
QURE uniQure N.V.	$1.6B	— (loss-making)	— (loss-making)	+11.00% (above 0%: growing)	n/m	+27.66% (above 0%: growing)	94.01%	(893.73%)	Compare
KRSA Korsana Biosciences, Inc.	$1.5B	— (loss-making)	— (loss-making)	−43.24% (below 0%: shrinking)	n/m	−184.69% (below 0%: shrinking)	100.00%	0.00%	Compare
MAZE Maze Therapeutics, Inc.	$1.5B	— (loss-making)	—	—	n/m	+50.21% (above 0%: growing)	100.00%	0.00%	Compare
ABSI Absci Corporation	$1.5B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)	Compare
Median of peers	$1.6B	—	—	−32.51%	—	−54.43%	100.00%	(655.49%)

All 614 Biotechnology stocks →

Intellia Therapeutics, Inc. (NTLA) key facts

Concern: Intellia Therapeutics, Inc. reported a net loss of $412.7 million, or a loss of $3.81 per share, for fiscal 2025.
Strength: Intellia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.7 million, up 16.9% from fiscal 2024.
Intellia Therapeutics, Inc. (NTLA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NTLA traded at $11.42, a market capitalization of $1.6 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 25.6× sales.
Return on equity was −53.5% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −1.93 (distress zone) for fiscal 2025.